Loading page content…
Loading page content…
5 matching contracts · Updated daily · Contracts Finder + Find a Tender Service
Genomics England are looking for a provider to support in digitising all the histopathology slides from the participants of the 100,000 Genomes Project so they can be transferred to the multi-modal research environment. The multi-modal project provides an enriched data set for cancer research by adding of imaging data from pathology slides and radiology images (e.g., x-ray, CT and MRI) alongside whole genome data. The multi-modal project aims are: - Complete the scanning and digitisation of the remaining 200,000 histopathology slides for the 100,000 Genomes Project participants. - Make accessible to researchers a secure library of linked genomic, clinical and imaging cancer data accompanied with the tooling needed to accelerate the understanding of the morphological, genomic and clinical changes that occur in cancer. - Lead the research community to generate new insights from the data to support diagnostic, prognostic and precision medicine discovery.
£2,250,000
Contract value
Genomics England seeks to implement a query layer to sit on top of a single location as tool that allows users or other apps to query the data. This means that the actual data can remain in place while the query layer handles providing the correct access and views of the data. The query layer will allow for simplified access control that can be rolled out downstream, scaling up and down on demand by controlling number of nodes and make it significantly easier to manage changes either to front end applications or upstream with ETL pipeline. The contract will be for provision of an API, implementation of the solution plus 5 years of licencing and support.
£1,500,000
Contract value
Genomics England are procuring a Researcher Platform, i.e. a coherent and interoperable set of tools to access, visualise, and analyse research data. Continuing our alignment with the government “cloud-first” strategy, the Researcher Platform will leverage the underlying cloud infrastructure which is procured separately. The Researcher Platform we are seeking to procure includes specialised tools, features to promote collaboration, and scientifically focused user interfaces missing from the standard cloud provider’s toolkits. This will result in easier onboarding and adoption, better user experience, larger reach and scale-up. The procurement of the Researcher Platform is driven by Genomics England's commitment to serving Users. We aim to provide a secure, user-friendly platform that caters to varying technical abilities, ensuring that all users can effectively analyse data. This means procuring a platform with an optimal set of tools and capabilities to be leveraged to cater for these many varying needs and collaborating with a mature third-party provider that is willing to follow and implement the innovations that can improve user experience and research output. During the Contract Term the successful Supplier shall develop, Test, deploy, and support a Researcher Platform for a minimum of 600 Monthly Active Users over the Contract Term, rising to 2000 Monthly Active Users by the end of a possible five-year Contract Term. The Researcher Platform will conform with the requirements set out in the tender documentation. The expected contract signature date is April 2026, and the expected implementation period is up to 10 months. The Initial Term of the Contract from the Service Commencement Date will be three years, with the opportunity to extend by up to an additional two years, making the total possible Contract Term five years. After the Service Commencement Date, the successful Supplier will continue to develop, improve, and maintain the Researcher Platform, and provide the support services in accordance with the Contract.
£14,400,000
Contract value
Genomics England is procuring long-read whole genome sequencing services. In partnership with the NHS and other stakeholders, we are co-designing and delivering a national research study, the Generation Study, involving up to 100,000 newborns to understand the role of whole genome sequencing to achieve more timely diagnosis of rare conditions and access to early intervention, enabling faster and better care for babies born with rare childhood onset diseases. The Generation Study aims to assess the benefits, challenges, and feasibility of integrating whole genome sequencing into newborn screening to enhance the early diagnosis and treatment of rare genetic conditions. If successful, the study could establish the foundation for the world's first national newborn screening program incorporating whole genome sequencing. The study also aims to understand how, with consent, newborns' genomic and health data could be used for research to enable new diagnostic discoveries and treatments to be developed. As part of the consent to the study mothers are asked for permission to retain the baby's data and sample and link it to clinical data over the course of their life and the ability to recontact them with further research opportunities. The study will provide an invaluable dataset to researchers across industry and academia, and we have the opportunity to conduct further studies in a subset of these families to maximise the future impact to patients, researchers and the NHS. Deepening our dataset, including by introducing new modalities, is a priority for industry. To do this, we to plan to develop an enhanced longitudinal birth cohort (Babies in Focus) in a subset of participants in the next five years. This will begin with conducting long-read whole genome sequencing for at least 2,000 samples across two long-read technologies. This will help inform us of the plans for the larger funding that is being requested as part of the 2026-2030 spending review. These services will be split into two lots: Lot 1: 1,000 samples to be delivered to the supplier and sequenced between 5 January 2026 and 31 March 2026. An earlier start date may be mutually agreed by the Supplier and the Authority if implementation is completed before 5 January 2026. This lot has an estimated value of £1.4M. Lot 2: 1,000 samples to be delivered and sequenced between 1 April 2026 and 1 September 2026. An earlier start date may be mutually agreed by Supplier and the Authority, subject to the Supplier's willingness and capability, and Authority funding. This lot has an estimated value of £1.4M There is an optional extension (volume to be confirmed) of up to a total of 1,000 additional samples, valued at £1.4M. These optional extension volumes may be awarded to one or split across both lots. These optional volumes must be delivered by 1 March 2027.
£4,200,000
Contract value
This procurement is for Enterprise ITSM tooling and licences and CMDB tooling and licences, including service design, delivery/project management, implementation, and data migration support. Genomics England is exploring the Enterprise ITSM and does not currently have a configuration management data base (CMDB), which is a fundamental piece of functionality. We are seeking proposals for CMDB solutions which will be used to maintain, monitor, and obtain a better view of our environment. The solution will provide details of the machines on the network, software they're running, and expiry dates, and then link back to our contracts to provide asset numbers of kit etc. Software, licensing, and support will need to be procured to meet this project's needs.
£2,250,000
Contract value